Asset Details
Do you wish to reserve the book?
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
Do you wish to request the book?
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
2023
Overview
Background
Malaria control is highly dependent on the effectiveness of artemisinin-based combination therapy (ACT), the current frontline malaria curative treatment. Unfortunately, the emergence and spread of parasites resistant to artemisinin (ART) derivatives in Southeast Asia and South America, and more recently in Rwanda and Uganda (East Africa), compromise their long-term use in sub-Saharan Africa, where most malaria deaths occur.
Methods
Here, ex vivo susceptibility to dihydroartemisinin (DHA) was evaluated from 38
Plasmodium falciparum
isolates collected in 2017 in Thiès (Senegal) expressed in the Ring-stage Survival Assay (RSA). Both major and minor variants were explored in the three conserved-encoding domains of the
pfkelch13
gene, the main determinant of ART resistance using a targeted-amplicon deep sequencing (TADS) approach.
Results
All samples tested in the ex vivo RSA were found to be susceptible to DHA (parasite survival rate < 1%). The non-synonymous mutations K189T and K248R in
pfkelch13
were observed each in one isolate, as major (99%) or minor (5%) variants, respectively.
Conclusion
The results suggest that ART is still fully effective in the Thiès region of Senegal in 2017. Investigations combining ex vivo RSA and TADS are a useful approach for monitoring ART resistance in Africa.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Animals
/ Antimalarials - pharmacology
/ Antimalarials - therapeutic use
/ Artemisinin partial resistance
/ Artemisinins - therapeutic use
/ Biomedical and Life Sciences
/ Consent
/ Control
/ High-Throughput Nucleotide Sequencing
/ Humans
/ Identification and classification
/ Malaria
/ Malaria, Falciparum - parasitology
/ Mutation
/ Protozoan Proteins - genetics
/ Protozoan Proteins - therapeutic use
/ Senegal
/ Survival
/ Targeted-amplicon deep sequencing
/ Uganda
